

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	LICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/934,604	09/934,604 08/23/2001		Edwin Mellor Southern	2001_1178	9336	
513	7590	12/15/2003		EXAMINER		
WENDEROTH, LIND & PONACK, L.L.P.				HORLICK, KENNETH R		
SUITE 800	2033 K STREET N. W. SUITE 800				PAPER NUMBER	
WASHING	WASHINGTON, DC 20006-1021				1637	

DATE MAILED: 12/15/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

U.S. Patent and Trademark Office PTOL-326 (Rev. 11-03)

3) ☑ Information Disclosure Statement(s) (PTO-1449) Paper No(s) • (dpuqes)

6) Other:

Art Unit: 1637

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claim 12 is rejected under 35 U.S.C. 102(e) as being anticipate by Nikiforov et al. (US 5,679,524).

This claim is drawn to an array of oligonucleotides wherein each one has a 3' nucleotide residue through which it is covalently attached to a support and a 5' nucleotide residue which is phosphorylated.

Nikiforov et al. disclose attachment of oligonucleotides to a solid support, wherein the 3' end is attached to said support and the 5' end is phosphorylated (see, for example, Fig. 1, top). This patent also discloses that oligonucleotides may be immobilized on the solid support "in specific patterns", i.e., as an array (see column 11, lines 6-64).

2. With respect to the above rejection, the arguments of the response filed 09/16/03 have been fully considered, but are not found persuasive. The response argues that "...there is no direct and unambiguous teaching in this passage that the Nikiforov product should contain different immobilized oligo sequences." However, the Office disagrees; it is submitted that the teaching "...oligonucleotides may also be applied to these formats in specific patterns using technologies such as ink-jet printing or

Application/Control Number: 09/934,604 Page 3

Art Unit: 1637

photolithography" (column 11, line 58) clearly covers arrays of <u>different</u> oligonucleotides, as the noted technologies were indisputably well known to one of ordinary skill in the art at the time of the invention to be used for this purpose.

## THE FOLLOWING IS A NEW GROUND OF REJECTION NECESSITATED BY THE AMENDMENT

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 14-28 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 6,307,039. Although the conflicting claims are not identical, they are not patentably distinct from each other because of a species-genus type relationship.

4. Claims 14-28 are free of the prior art, but are rejected for other reasons. No claims are allowable.

Art Unit: 1637

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kenneth R Horlick whose telephone number is 703-308-3905 (571-272-0784 in Jan. 2004). The examiner can normally be reached on Monday-Thursday 6:30AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1637

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Yenth. Hahl, Ph.D. Kenneth R Horlick

**Primary Examiner** 

Art Unit 1637

12/01/03